{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T21:53:53Z","timestamp":1764194033125},"reference-count":30,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2013,5,29]],"date-time":"2013-05-29T00:00:00Z","timestamp":1369785600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Asia-Pac J Clncl Oncology"],"published-print":{"date-parts":[[2016,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aims<\/jats:title><jats:p>Cyclophosphamide was widely used as a single agent prior to the advent of platinum\u2010based regimens for epithelial ovarian cancer, and, in combination with platinum, prior to the adoption of platinum and paclitaxel as standard first\u2010line therapy. As cyclophosphamide currently has no defined role in ovarian cancer we aimed to assess its activity in women with recurrent disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective review was conducted of patients from three centers in <jats:styled-content style=\"fixed-case\">M<\/jats:styled-content>elbourne, <jats:styled-content style=\"fixed-case\">A<\/jats:styled-content>ustralia who had received oral cyclophosphamide treatment for recurrent ovarian cancer. The primary end\u2010point was response rate to oral cyclophosphamide (150\u2009mg p.o. day 1\u201314) based on Gynecologic Cancer InterGroup (<jats:styled-content style=\"fixed-case\">GCIG) CA125<\/jats:styled-content> and\/or Response Evaluation Criteria in Solid Tumors (<jats:styled-content style=\"fixed-case\">RECIST<\/jats:styled-content>) criteria. Secondary end\u2010points included overall and progression\u2010free survival and toxicity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In all, 26 patients were identified and 23 patients were evaluable for response. The median number of prior chemotherapy regimens was three (range 1\u20136). The response rate to oral cyclophosphamide was 44% with 10 of the 23 patients achieving a partial response (<jats:styled-content style=\"fixed-case\">PR<\/jats:styled-content>) based on <jats:styled-content style=\"fixed-case\">GCIG<\/jats:styled-content> (<jats:styled-content style=\"fixed-case\">CA125<\/jats:styled-content>) criteria. The median number of cycles received was three (range 1\u201316). Cyclophosphamide showed activity both in patients with platinum\u2010sensitive (seven of 13 <jats:styled-content style=\"fixed-case\">PR<\/jats:styled-content>) and resistant or refractory disease (three of 10 <jats:styled-content style=\"fixed-case\">PR<\/jats:styled-content>). There was no grade 3 or 4 toxicity but two patients ceased cyclophosphamide due to less severe non\u2010hematological toxicity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Single agent oral cyclophosphamide is active and well tolerated in recurrent ovarian cancer. Further investigation of oral cyclophosphamide in patients with platinum\u2010sensitive and platinum\u2010resistant disease is warranted.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ajco.12074","type":"journal-article","created":{"date-parts":[[2013,5,30]],"date-time":"2013-05-30T05:03:03Z","timestamp":1369890183000},"source":"Crossref","is-referenced-by-count":23,"title":["Oral cyclophosphamide in recurrent ovarian cancer"],"prefix":"10.1111","volume":"12","author":[{"given":"Despina","family":"Handolias","sequence":"first","affiliation":[{"name":"Royal Women's Hospital  Melbourne Victoria Australia"},{"name":"Peter MacCallum Cancer Centre  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Quinn","sequence":"additional","affiliation":[{"name":"Royal Women's Hospital  Melbourne Victoria Australia"},{"name":"University of Melbourne  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serene","family":"Foo","sequence":"additional","affiliation":[{"name":"Mercy Hospital for Women  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Mileshkin","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre  Melbourne Victoria Australia"},{"name":"University of Melbourne  Melbourne Victoria Australia"},{"name":"Mercy Hospital for Women  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Grant","sequence":"additional","affiliation":[{"name":"University of Melbourne  Melbourne Victoria Australia"},{"name":"Mercy Hospital for Women  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaelle","family":"Dutu","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danny","family":"Rischin","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre  Melbourne Victoria Australia"},{"name":"University of Melbourne  Melbourne Victoria Australia"},{"name":"Mercy Hospital for Women  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,5,29]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1998.710"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.3.389"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1997.4708"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2006.04.002"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(94)90489-8"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1048-891x.2005.14401.x"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1994.1098"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.7-suppl_5-20"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/00003081-196806000-00001"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)04119-1"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199601043340101"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.9.699"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.1939"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1159\/000320602"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-3039"},{"key":"e_1_2_6_17_1","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2010.28.15_suppl.1018","article-title":"Safety and efficacy of the oral PARP inhibitor olaparib (AZD2281) in combination with paclitaxel for the first\u2010 or second\u2010line treatment of patients with metastatic triple\u2010negative breast cancer: results from the safety cohort of a phase I\/II multicenter trial","volume":"28","author":"Dent R","year":"2010","journal-title":"J Clin Oncol"},{"key":"e_1_2_6_18_1","first-page":"15S","article-title":"A phase I combination study of olaparib (AZD2281; KU\u20100059436) and cisplatin (C) plus gemcitabine (G) in adults with solid tumors","volume":"28","author":"Giaccone G","year":"2012","journal-title":"J Clin Oncol"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.28.15_suppl.2514"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-2821"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djh081"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-010-0094-1"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-7-65"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2009.21.5.566"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2007.07.017"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-009-0363-5"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2012.04.003"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.5719"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.1456"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2010.086405"},{"key":"e_1_2_6_31_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.5020","article-title":"Randomized trial of oral cyclophosphamide (C) with or without veliparib (V), an oral poly (ADP\u2010ribose) polymerase (PARP) inhibitor, in patients with recurrent BRCA\u2010positive ovarian, or primary peritoneal or high\u2010grade serous ovarian carcinoma","volume":"30","author":"Kummar S","year":"2012","journal-title":"J Clin Oncol"}],"container-title":["Asia-Pacific Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fajco.12074","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fajco.12074","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.12074","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T11:47:41Z","timestamp":1694346461000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajco.12074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,29]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["10.1111\/ajco.12074"],"URL":"https:\/\/doi.org\/10.1111\/ajco.12074","archive":["Portico"],"relation":{},"ISSN":["1743-7555","1743-7563"],"issn-type":[{"type":"print","value":"1743-7555"},{"type":"electronic","value":"1743-7563"}],"subject":[],"published":{"date-parts":[[2013,5,29]]}}}